The UK’s MHRA approval of Tauvid comes four years after it was approved by the FDA. Credit: Ralf Liebhold via Shutterstock.

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Tauvid (flortaucipir), a diagnostic imaging agent developed by Eli Lilly subsidiary Avid Radiopharmaceuticals, to identify whether patients with memory problems may have Alzheimer’s disease.

The agent is designed for positron emission tomography (PET) imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs), a primary marker of Alzheimer’s disease.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Tauvid is given by injection to patients with memory problems about 80 minutes before obtaining an image from a PET scan.

Tauvid received approval from the US Food and Drug Administration (FDA) in 2020.

The MHRA said the approval was based on a performance review study that found that flortaucipir PET scans had a sensitivity of 92% in the ability to detect significant buildup of abnormal tau protein in the brain.

However, the agency stressed that flortaucipir PET scan results alone cannot confirm or refute a diagnosis of Alzheimer’s disease in patients with cognitive impairment and that doctors must use the scans alongside other available clinical evaluation and diagnostic tools.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Julian Beach, interim executive director of healthcare quality and access at the MHRA, said: “We are focused on providing UK patients access to safe and effective medicines.

“We’re assured that the appropriate regulatory standards for the approval of this medicine have been met.  As with all products, we will keep its safety under close review.’’

Alzheimer’s is the most common form of dementia. Alzheimer’s Disease International (ADI) estimates there were more than 55 million people worldwide living with dementia in 2020 and anticipates this number will almost double every 20 years, reaching 78 million in 2030 and 139 million in 2050.

In related Alzheimer’s diagnostic news, Veravas and Phanes Biotech recently announced a partnership to develop a blood-based tau pathology test for Alzheimer’s disease detection.

In addition, Roche shared new late-breaking data from a prospective trial at the recent 17th Clinical Trials in Alzheimer’s Disease Congress in Madrid, Spain, showing that its Elecsys amyloid plasma panel can rule out Alzheimer’s disease with a high negative predictive value of 96.2%.